Following the introduction of the anti-VEGF therapies over a decade ago, the wet AMDmarket has been dominated by three therapies—Roche/Genentech/Novartis’s Lucentis, approved for wet AMD, Roche/Genentech/Chugai’s Avastin, approved for cancer but commonly compounded and used off-label for wet AMD, and, most recently, Regeneron/Bayer HealthCare/Santen’s Eylea, which has experienced strong and continued uptake at the expense of the other drugs within this class. Although the majority of AMDpatients are diagnosed with the dry form of AMD
age-related macular degeneration
, management of this disease type is limited to minimally effective vitamin formulations because no prescription pharmacotherapies are approved for this large and underserved subpopulation. However, the pipeline features a growing number of novel agents targeting the advanced form of dry AMD (i.e., GA), as well as therapies for wet AMD.
- Do KOLs perceive any differences between the mainstays Avastin, Eylea, and Lucentis? How is their use expected to change, if at all, over the next ten years?
- Biosimilar versions of Eylea and Lucentis are forecast to launch within the next ten years. What is the likely impact of these therapies on current and emerging VEGFinhibitors?
- Therapies with longer dosing intervals than offered by current therapies represents a substantial unmet need in wet AMD. To what extent are the emerging VEGF inhibitors Novartis’s brolucizumab and Allergan’s abicipar pegol expected to capitalize on this unmet need?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.